
    
      The primary objective of this study is to assess efficacy relative to placebo of GP MDI in
      subjects with moderate to severe chronic obstructive pulmonary disease (COPD) within the
      range of doses evaluated in this protocol. To this end, each dose of GP MDI will be compared
      to placebo with respect to the primary efficacy endpoint, FEV1 AUC0-12 relative to baseline.
    
  